Acellular vaccines represent a significant advancement in immunization, utilizing purified components of pathogens to induce an immune response without the need for whole live organisms. Unlike traditional vaccines that use weakened or inactivated microbes, acellular vaccines focus on specific components such as proteins or sugars that trigger protective immunity. These vaccines are designed to provide a safer alternative by minimizing the risk of adverse reactions associated with live vaccines. Pertussis (whooping cough) vaccines are prominent examples of acellular vaccines, consisting of purified pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae. Acellular vaccines have demonstrated effectiveness in preventing infectious diseases while reducing the likelihood of side effects. Their development has been crucial in enhancing vaccine safety, especially for vulnerable populations like infants. The modular nature of acellular vaccines allows for targeted immunity, offering protection against specific virulence factors.
Khursheed Nadeem Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Overcoming biophysical characterization challenges of small antigens in dilute vaccine formulations
Eric Kemp, Merck & Co., United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : A combined LC-MS and immunoassay approach to characterize preservative-induced destabilization of human papillomavirus virus-like particles adsorbed to an aluminum-salt adjuvant
Ria T Caringal, University of Kansas, United States